Acelyrin (SLRN) Stock Price, News & Analysis

Company Overview

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Key Stats

• Today's Range: $2.27 to $2.27
• 50-Day Range: $2.05 to $2.58
• 52-Week Range: $1.85 to $7.25
• Volume: N/A
• Average Volume: 1.26 million shs
• Market Capitalization: $229.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.60
• Consensus Rating: Hold

SLRN Stock Analysis - Frequently Asked Questions

How have SLRN shares performed this year?

Acelyrin's stock was trading at $3.14 at the beginning of 2025. Since then, SLRN stock has decreased by 27.7% and is now trading at $2.27.
View the best growth stocks for 2025 here.

How were Acelyrin's earnings last quarter?

Acelyrin, Inc. (NASDAQ:SLRN) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.40.

When did Acelyrin IPO?

Acelyrin (SLRN) raised $540 million in an initial public offering (IPO) on Friday, May 5th 2023. The company issued 30,000,000 shares at $18.00 per share.

Who are Acelyrin's major shareholders?

Acelyrin's top institutional shareholders include T. Rowe Price Investment Management Inc. (4.61%), Velan Capital Investment Management LP (3.34%), Alyeska Investment Group L.P. (0.61%) and Charles Schwab Investment Management Inc. (0.54%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Mina Kim, Daniel J Becker and Ronald Oyston.
View institutional ownership trends.

How do I buy shares of Acelyrin?

Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Acelyrin own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acelyrin investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 6/15/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLRN
• CIK: 1962918
• Web: www.acelyrin.com
• Phone: 805-730-0360
• Fax: N/A
• Employees: 135
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.60
• High Stock Price Target: $20.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +322.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$381.64 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -44.12%
• Return on Assets: -39.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.15
• Quick Ratio: 7.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.74 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 100,954,000
• Free Float: 86,682,000
• Market Cap: $229.17 million
• Optionable: Optionable
• Beta: 1.07